Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions (Q36586901)

15 August 2017

1 reference

title

Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions (English)

1 reference

15 August 2017

1 reference

Chantal Bernard-Marty

series ordinal

1

object named as

Chantal Bernard-Marty

1 reference

15 August 2017

Fabienne Lebrun

2

1 reference

15 August 2017

Ahmad Awada

series ordinal

3

1 reference

15 August 2017

Martine J Piccart

series ordinal

4

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

66

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1577-1591

1 reference

Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates

15 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666120-00004

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666120-00004

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

12 December 2020

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects

1 reference

12 December 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

1 reference

12 December 2020

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

1 reference

12 December 2020

HER-2-targeted therapy: lessons learned and future directions.

1 reference

12 December 2020

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

1 reference

12 December 2020

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

1 reference

12 December 2020

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.

1 reference

12 December 2020

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

12 December 2020

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Prognostic Correlation of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in 1307 Primary Breast Cancers

1 reference

12 December 2020

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

12 December 2020

Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).

1 reference

12 December 2020

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

1 reference

12 December 2020

Dysregulation of cellular signaling by HER2/neu in breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer

1 reference

12 December 2020

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

12 December 2020

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

12 December 2020

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer

1 reference

12 December 2020

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

12 December 2020

Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models

1 reference

12 December 2020

Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial

1 reference

12 December 2020

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

1 reference

12 December 2020

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

1 reference

12 December 2020

Common and distinct elements in cellular signaling via EGF and FGF receptors

1 reference

12 December 2020

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

12 December 2020

Biologic and therapeutic role of HER2 in cancer

1 reference

12 December 2020

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwa

1 reference

12 December 2020

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

12 December 2020

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

12 December 2020

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

12 December 2020

Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

1 reference

12 December 2020

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

12 December 2020

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

1 reference

12 December 2020

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

12 December 2020

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

1 reference

12 December 2020

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

12 December 2020

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

1 reference

12 December 2020

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

12 December 2020

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

1 reference

12 December 2020

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

1 reference

12 December 2020

ErbB receptors: directing key signaling networks throughout life

1 reference

12 December 2020

Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin

1 reference

12 December 2020

A model-based approach for assessing in vivo combination therapy interactions

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

1 reference

12 December 2020

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

12 December 2020

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

12 December 2020

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

12 December 2020

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

1 reference

12 December 2020

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

12 December 2020

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

12 December 2020

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

12 December 2020

Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study

1 reference

12 December 2020

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

1 reference

12 December 2020

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

1 reference

12 December 2020

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

1 reference

12 December 2020

Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules

1 reference

12 December 2020

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines

1 reference

12 December 2020

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

1 reference

12 December 2020

4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study

1 reference

12 December 2020

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

1 reference

12 December 2020

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

12 December 2020

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

1 reference

12 December 2020

Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer

1 reference

12 December 2020

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

12 December 2020

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

12 December 2020

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

1 reference

12 December 2020

Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

1 reference

12 December 2020

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

1 reference

12 December 2020

10.2165/00003495-200666120-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1015571718

0 references

1 reference